← boardnext 2026-11-20
SKYE
Skye Bioscience, Inc.distress 6/10 · elevated risk$0.67+4%today-86% from 52w high
Lead: Obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$17M
Runway
0.4 yrs
Shares 1y
+13%
Price & events
-36.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.1%
1D
+5.9%
1W
-4.8%
1M
-25.9%
3M
-34.0%
6M
-84.7%
1Y
-89.0%
2Y
-98.2%
5Y
-93.3%
All
Overview
- Market Cap
- $23.42M
- Volume
- 13.86K
- 52 Week Range
- $0.58 – $4.75
- Total Shares
- 35.14M
- Float Shares
- 22.97M
- Short %
- 3.80%
- % Held by Insiders
- 1.17%
- % Held by Institutions
- 46.00%
- RVOL
- 0.11x
- Beta
- 2.94
Pipeline stages · 1 programs
Nimacimab injection, Nimacimab 300 mg injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-20 Estimated 50% readout ~2027-01-04 | Phase 2 | Nimacimab injection, Nimacimab 300 mg injection | Obesity | — | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 3
- Q3 2026Guided 70%readoutPhase 2nimacimab · Full topline data from Phase 2a extension study including nimacimab monotherapy and 13-week off-therapy follow-upSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- October 6, 2025readoutPhase 2nimacimab · Topline Phase 2a data for nimacimab monotherapy and combination clinical trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $7 (+1001% upside) · 6 analysts
- 2025-09-30HC Wainwright & Co.Buy
- 2025-08-15Evercore ISI GroupOutperform
- 2025-06-24JMP SecuritiesMarket Outperform
- 2025-03-21Craig-HallumBuy
- 2025-03-21Citizens Capital MarketsMarket Outperform
- 2025-02-28William BlairOutperform
Competitors — Obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-08Skye Bioscience (SKYE) Nudges Higher as Biotech Sector Finds Footing - Swing Entry Signals - dars.gov.et
- 2026-06-25SKYE Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-23Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall - TradingView
- 2026-06-23Skye Bioscience Moves Listing to Nasdaq Capital Market - TipRanks
- 2026-06-23Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices - Stock Titan
- 2026-06-18Skye Bioscience, Inc. Stock 12‑Month Price Target Cut to $7.33, Implies 937% Upside - TradingView
- 2026-05-29Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase - Stock Titan
- 2026-05-28Skye Bioscience (SKYE) Holds Above Support After Modest Gain - Institutional Volume - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.